Press Releases

Press Release: PersImmune PACTN Clinical Trial for MDS, July 25, 2019

Personalized Adoptive T Cell Therapy: A New, Rational Approach to Immunotherapy, Select Science, May 15, 2019

Presentations

A Genomics-based Approach to Cellular Immunotherapy for Acute Myeloid Leukemia. International Congress on Immuno-Oncology. Mexico City, October, 2015.

Targeted Cellular Immunotherapy for AML: A Genomics-based Approach. Emily Cooley Award Lecture; AABB Annual Meeting, Anaheim, CA; October, 2015.

Personalized neoantigen-specific adoptive T cell therapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Keystone Symposium on Cancer Immunology and Immunotherapy, Whistler, Canada; March 2017.

Personalized Neoantigen-Specific Adoptive T Cell Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome: Evidence for T Cell Anti-Stem Cell Specificity: Oral abstract; AABB Annual Meeting, San Diego, CA; October 2017.

Workshop on T cell Immunotherapy (3 lectures). Neoantigen Summit, Boston, MA, November, 2018.

Personalized Adoptive Cell Therapy targeted to patient-specific cancer cell Neoantigens. Neoantigen Summit, Boston, MA, November, 2018.

A Phase I Clinical Trial of Personalized Adoptive Cellular Therapy Targeting Myelodysplastic Syndrome (MDS) Stem Cell Neoantigens (PACTN). ASH Annual Meeting, San Diego, CA; December 2018.

Personalized, Adoptive immunotherapy by Cytotoxic T cells that are targeted to patient-specific cancer cell Neoantigens (PACTN) in patients with myelodysplastic syndromes (MDS). International Immunotherapy Congress, San Diego, CA, March, 2019.

PD-L1: A Side Effect of T Cell Engagement or a Main Player in MDS Tumor Immune Evasion? AACR Immune Cell Therapies for Cancer, San Francisco, CA; July 2019.